In August, Danaher completed the acquisition of Beckman Coulter, which makes products used in biomedical testing.The deal was a cash tender offer for all of Beckman Coulter's outstanding shares of common stock at a purchase price of $83.50 per share for a total consideration of $6.9 billion, including debt assumed and net of cash acquired. Of the 24 analysts covering Danaher, 75% rate it a buy. On average, analysts polled by Bloomberg expect the stock to gain 17.4% to $55.95 in the coming 12 months.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts